Scott Liebman

September 12, 2024 | New York Law Journal

Sheppard Mullin attorneys discuss 'Loper Bright Enterprises v. Raimondo' and include the considerations stemming from the decision, both generally and with respect to FDA practice, specifically. They write: "Now, after having spent the summer pouring over cases, articles, and thought leadership on the matter, we're not sure the win is so sweeping—especially in the U.S. Food & Drug Administration arena."

By Scott Liebman, Dominick DiSabatino and Audrey Mercer

8 minute read

January 09, 2023 | New York Law Journal

In 2022, the Office of Inspector General and at least two federal courts took a clear stance against pharmaceutical manufacturers' attempts to offer cost-sharing subsidies to Medicare beneficiaries for certain drugs, but the industry is fighting back. Pharmaceutical manufacturers and lobbying groups are challenging these administrative restrictions in a concerted effort to increase access to life-saving medications.

By Dominick DiSabatino, Audrey Crowell and Scott Liebman

15 minute read

March 23, 2022 | New York Law Journal

Medical device manufacturers should pay close attention to this trend when considering trial designs and patient populations.

By Scott Liebman and Dominick DiSabatino

7 minute read